Your Global Leader in Stem Cell Market Research
Learn more about multiple sclerosis treatment and how stem cells can help in treating this condition here.
in this article:
Hematopoietic stem cells (HSCs) are defined as stem cells that have a preference for becoming cells of the blood and immune system, such as white blood cells, red blood cells, and platelets. Found in the peripheral blood and bone marrow, hematopoietic stem cells are also present in plentiful supply within the umbilical cord blood of newborn babies.
For the past thirty years, cord blood has been used within transplant medicine, including for the treatment of leukemia and other blood diseases. For most conditions in which a bone marrow or peripheral blood stem cell transplant is an option, a cord blood transplant is a potential alternative.
In this article:
The global cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the USA, followed by the establishment of cord blood banks across the globe. However, the history of cord blood stem cell transplantation begins much earlier than that.
In this article:
Stem cell clinical trials are research studies that involves human patients. Learn a simple tool to identify stem cell clinical trials for your condition.
Are you or a loved on suffering from arthritis, multiple sclerosis (MS), Alzheimer’s disease, dementia, or other chronic condition? If so, how do you find a stem cell clinical trial? This is a question that we get asked on a regular basis by readers of our site.
This article provides all the answers, including links to global registries to find a trial within your region and direct links to clinical trials by condition.
Use this guide to get started with your search for a stem cell clinical trial near you.
Gamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company is developing a diverse clinical pipeline based on its proprietary NAM technology platform. It lead program, NiCord®, is now in Phase 3 development for allogeneic bone marrow transplantation.
NiCord® was granted Breakthrough Therapy Designation by the FDA, as well orphan drug designation by the European Medicines Agency (EMA). [Read more…]
